Lecanemab is an anti-amyloid monoclonal antibody, recently approved in the UK as a treatment for mild cognitive impairment (MCI) and mild dementia due to Alzheimer’s disease (AD) in adults who are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback